The stock of Skye Bioscience Inc (SKYE) has gone down by -3.12% for the week, with a 5.85% rise in the past month and a -21.94% drop in the past quarter. The volatility ratio for the week is 9.00%, and the volatility levels for the past 30 days are 8.66% for SKYE. The simple moving average for the last 20 days is 1.88% for SKYE stock, with a simple moving average of -34.76% for the last 200 days.
Is It Worth Investing in Skye Bioscience Inc (NASDAQ: SKYE) Right Now?
SKYE has 36-month beta value of 1.68. Analysts have mixed views on the stock, with 4 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for SKYE is 17.86M, and currently, short sellers hold a 17.43% ratio of that float. The average trading volume of SKYE on June 12, 2025 was 698.72K shares.
SKYE) stock’s latest price update
Skye Bioscience Inc (NASDAQ: SKYE)’s stock price has plunge by -8.44relation to previous closing price of 2.37. Nevertheless, the company has seen a -3.12% plunge in its stock price over the last five trading sessions. zacks.com reported 2025-05-23 that NVO, CRBP and SKYE are tapping into the booming obesity market with novel CBD-based therapies, offering alternatives amid intensifying GLP-1 competition.
Analysts’ Opinion of SKYE
Scotiabank, on the other hand, stated in their research note that they expect to see SKYE reach a price target of $20. The rating they have provided for SKYE stocks is “Sector Outperform” according to the report published on September 30th, 2024.
JMP Securities gave a rating of “Mkt Outperform” to SKYE, setting the target price at $15 in the report published on September 10th of the previous year.
SKYE Trading at 16.80% from the 50-Day Moving Average
After a stumble in the market that brought SKYE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -80.55% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at SKYE starting from Diep Tuan Tu, who sale 19,489 shares at the price of $4.99 back on Nov 18 ’24. After this action, Diep Tuan Tu now owns 82,259 shares of Skye Bioscience Inc, valued at $97,250 using the latest closing price.
Diep Tuan Tu, the Chief Development Officer of Skye Bioscience Inc, sale 85 shares at $5.55 during a trade that took place back on Nov 15 ’24, which means that Diep Tuan Tu is holding 101,748 shares at $472 based on the most recent closing price.
Stock Fundamentals for SKYE
The total capital return value is set at -0.0. Equity return is now at value -47.27, with -40.91 for asset returns.
Based on Skye Bioscience Inc (SKYE), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -22.34. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -10.47.
The liquidity ratio also appears to be rather interesting for investors as it stands at 11.85.
Conclusion
To put it simply, Skye Bioscience Inc (SKYE) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
